The primary therapeutic domain of this medication is the symptomatic management of allergic rhinitis, commonly known as hay fever, when the condition is characterized by a significant combination of symptoms. The medication is commonly used across conditions presenting with acute or recurrent episodes of upper respiratory allergy symptoms.

Relief of Combined Allergic and Congestion Symptoms

This medication is generally used for managing symptoms that create noticeable physiological strain, particularly those associated with both seasonal and perennial allergic rhinitis when nasal congestion is a pronounced and problematic feature. It helps address a cluster of manifestations, including sneezing, a runny nose, an itchy nose or throat, and watery, itchy eyes. The combination is specifically intended for managing these symptom clusters when they occur alongside pronounced nasal and sinus congestion, contributing to improved comfort during periods of heightened symptoms.

“The medication helps contribute to easing the overall symptom load when symptoms become more noticeable during difficult episodes.”

Support During Acute Symptomatic Episodes

The extended-release formulation is relevant for managing symptoms that interfere with daily comfort over a longer timeframe. This benefit is relevant when short-term symptomatic assistance is needed during phases when symptoms become temporarily overwhelming, such as during intense allergy flares. It helps maintain a sense of stability when symptoms interfere with routine activities, supporting general well-being during symptomatic periods.

Quick Fact: Relief for Significant Nasal Congestion is a key focus for this combination.

Regulatory References

1. DailyMed drug label for Loratadine and Pseudoephedrine

Eligibility Map: Who can and cannot use Клариназе-12 — Official Regulatory Information

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and children 12 years of age and older.
Populations for whom use is not recommended	Children younger than 12 years of age (safety and efficacy not established).
Populations for whom use is contraindicated	Patients with severe hypertension, severe coronary artery disease, or known hypersensitivity to the drug or components.
	Patients receiving Monoamine Oxidase Inhibitors (MAOI) or within 14 days of cessation.
Condition-specific eligibility rules	Contraindicated in patients with narrow-angle glaucoma or urinary retention.
	Use should generally be avoided in patients with severe hepatic impairment.
Pregnancy and lactation eligibility status	Use during pregnancy is only acceptable if the potential benefit outweighs the risk; safe use is not established. Use is not recommended during lactation (breastfeeding).
Eligibility-related restrictions	Use must be judicious in patients with non-severe hypertension, diabetes mellitus, or hyperthyroidism.

---

Eligibility Classifications (High-Level)

Classification	Official Regulatory Wording (Examples)
Eligibility severity classification	Contraindicated, Not recommended, Should generally be avoided, Use judiciously.
Regulatory basis	Based on the official Prescribing Information / SmPC for the Loratadine/Pseudoephedrine extended-release combination.

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is established for use in individuals who are 12 years of age and older.
• Use is strictly prohibited for populations with severe cardiovascular or specific ocular/urinary conditions.
• Populations with severe organ impairment or those taking MAO inhibitors are explicitly excluded from using this medicine.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine through strict population-based classifications. These rules establish the approved age group and list high-risk medical conditions and concurrent drug use that formally prohibit or severely restrict eligibility for this fixed-dose product.

Interactions with other medicines and products

Regulatory documents establish the official interaction profile for Clarinase-12 (Loratadine and Pseudoephedrine sulfate) primarily based on the sympathomimetic and metabolic properties of its two active components.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of a hypertensive crisis resulting from the potentiation of the Pseudoephedrine component. This restriction also applies for 14 days following the discontinuation of MAOI therapy. Use with Ergot derivatives is also contraindicated, as the sympathomimetic component may enhance vasoconstrictive effects, increasing the risk of high blood pressure.

Pharmacokinetic and Pharmacodynamic Interactions

Substances known to inhibit hepatic metabolism, such as Ketoconazole, Erythromycin, and Cimetidine, are documented to increase the plasma AUC and Cmax of the Loratadine component by reducing its clearance. The Pseudoephedrine component may also reduce the antihypertensive effects of medicines like beta-blockers or Methyldopa. Additionally, co-administration with Digitalis (Digoxin) is associated with increased ectopic pacemaker activity.

Population and Timing Constraints

The product is generally advised to be avoided in patients with severe hepatic or renal impairment. The official label states that alcohol does not potentiate the psychomotor performance effects of the Loratadine component.

The mechanism of Клариназе-12 is defined by the complementary actions of its two components, each targeting a distinct physiological pathway to provide dual-pathway modulation.

Modulating the Peripheral H1 Inflammatory Cascade

The Loratadine component is a selective inverse agonist that acts primarily on peripheral histamine H1 receptors. By stabilizing these receptors in an inactive state, the drug interrupts the signaling cascade normally triggered by histamine, resulting in the modulation of capillary permeability and sensory nerve signaling. This mechanism is centered on the biochemical H1 component of the inflammatory response.

Activating alpha-Adrenergic Vascular Control

The Pseudoephedrine component is a sympathomimetic agent that exerts an agonist effect on alpha-adrenergic receptors found in the mucosal blood vessels. This action initiates the contraction of vascular smooth muscle, resulting in the vasoconstriction of arterioles and capillaries in the nasal lining. This mechanism directly causes the structural change of reduced mucosal tissue volume by mechanically reducing the blood volume and fluid retention in the tissue.

Official Administration Guidelines

Клариназе-12 (Loratadine 5 mg / Pseudoephedrine sulfate 120 mg) is administered strictly via the oral route using the extended-release tablet form. The official dosing regimen establishes a standardized usage pattern for adults and adolescents 12 years of age and older.

The medication is to be taken twice daily (BID), with doses separated by approximately 12 hours to maintain sustained action. The standard regimen is one tablet per dose, and the maximum limit is strictly two tablets in any 24-hour period.

Procedural and Duration Constraints

A critical administration principle is that the extended-release tablet must be swallowed whole and must not be divided, crushed, chewed, or dissolved, as this would compromise the controlled release mechanism. The tablet may be taken with or without food.

The administration protocol mandates that use is intended for short-term management only, and continuous treatment is typically restricted to a duration of about 10 days. This constraint structures the medicine's use as a temporary intervention.

While standard dosing applies to individuals 12 years and older, official documents advise caution, potential dose adjustment, or avoidance in patients with severe hepatic or renal impairment.

Claritin-D 12-Hour: Recent Clinical Evidence

---

Overview of Combination Therapy Research

Claritin-D 12-Hour is a combination product containing an antihistamine (loratadine) and a decongestant (pseudoephedrine). Clinical studies primarily investigate the distinct effects of these two components and their combined use in the management of allergic rhinitis and nasal congestion. Research on combination therapy generally examines how the ingredients may complement one another in addressing the multiple symptoms of seasonal allergies.

Efficacy and Symptom Relief Studies

Trials have focused on specific outcomes, including scores for nasal congestion, rhinorrhea (runny nose), sneezing, and ocular symptoms. Loratadine is commonly studied for its potential to relieve non-nasal allergy symptoms. Pseudoephedrine is studied for its vasoconstrictive properties, which may affect nasal airflow.

Research has explored the effect of the 12-hour sustained-release formulation. Studies have examined the duration of symptom relief observed over a 24-hour period, comparing the fixed-dose combination to placebo and sometimes to its individual components. Findings were analyzed across different patient subgroups defined by the severity of their symptoms.

Safety and Tolerability Profile

Clinical data reports on the common adverse events associated with both components. Sedation rates are evaluated, particularly in comparison to first-generation antihistamines. The decongestant component is associated with certain systemic effects, and trial data details the incidence of common events such as insomnia, dry mouth, and nervousness. Studies also evaluate changes in heart rate and blood pressure among trial participants to establish the overall tolerability profile.

Key Studies & References

1. Claritin-D® 12 Hour - DailyMed (FDA Labeling)
2. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis (RCT)
3. Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis (Trial Listing)

Common questions about Клариназе-12 (FAQ)

---

Q: Is Клариназе-12 the same as just taking a standard allergy pill?

No. This medication is described in official product information as a combination product that contains two active ingredients: an antihistamine (loratadine) to address allergy symptoms like sneezing and itching, and a decongestant (pseudoephedrine sulfate) to help relieve nasal stuffiness.

Q: Why does the packaging say '12'?

The number '12' in the product name is associated with the drug’s delivery system. Regulatory documents indicate that the extended-release formulation is designed to support sustained action over time, with doses typically separated by approximately 12 hours.

Q: Is Клариназе-12 available over the counter, or do you need a prescription?

According to the official marketing category, this type of product containing pseudoephedrine is typically sold behind the pharmacy counter without requiring a full prescription. Regulatory guidelines require products containing pseudoephedrine to be sold behind the pharmacy counter, with certain restrictions.

Q: How quickly does Клариназе-12 usually start working after taking it?

Studies examined in the product information report that the onset of nasal congestion relief was observed in trial participants within 30 minutes. This is based on measurements of the decongestant component's effects.

Q: Do people take Клариназе-12 for issues other than seasonal allergies?

Official product information states that the drug's use is limited to the relief of symptoms associated with seasonal allergic rhinitis (hay fever) and nasal congestion. The regulatory label does not list other approved conditions.

Q: Are there any long-term effects of using Клариназе-12 regularly?

The official administration guidelines mandate that continuous treatment is restricted to short-term use, typically around 10 days, according to the product label. Regulatory documents caution against long-term or indefinite use.

Q: Is it possible for Клариназе-12 to interact with common pain relievers like ibuprofen?

The official interaction profile lists specific drug classes that should be avoided. The label notes that the decongestant component may interact with other sympathomimetic drugs, which includes some cold or pain-relief preparations that also contain a decongestant. The label is silent on non-sympathomimetic pain relievers like ibuprofen.

Q: Does Клариназе-12 carry a risk of becoming dependent on it?

Official documents note that the antihistamine component has no known potential for misuse. However, the decongestant component, pseudoephedrine, is classified as a central nervous system stimulant, and regulatory documents note that it carries a documented risk for misuse at high doses.

Q: Where can I find the official regulatory information about Клариназе-12?

The complete, official regulatory and labeling information for this drug combination is maintained by government health bodies. In the United States, this information is publicly accessible and updated by the National Institutes of Health (NIH) on their DailyMed website.

Q: What is the difference between Клариназе-12 and other drugs with a similar name?

This specific combination product is characterized by its dosage strength (loratadine 5 mg and pseudoephedrine 120 mg) and its extended-release (12-hour) delivery system. Other products with similar names may contain different active ingredients, different strengths, or have a different release mechanism, such as a 24-hour formulation.

Q: How does the time-release feature of Клариназе-12 work?

The extended-release tablet is engineered so the loratadine is in the coating for immediate release. The pseudoephedrine sulfate is equally distributed between this coating and an inner core, allowing it to be released slowly over 12 hours to maintain therapeutic action.

Q: Are there any dietary restrictions mentioned in the official papers for Клариназе-12?

According to official product information, the tablet can be taken with or without food. There are no specific foods or drinks listed in the regulatory documentation as being officially required to avoid.

Q: Is it possible for Клариназе-12 to cause changes in mood?

Official labeling lists certain side effects related to the central nervous system. These include common events like nervousness, anxiety, fear, restlessness, and excitability. These effects are generally associated with the stimulating properties of the decongestant component.

Q: What is the purpose of the dye or coloring used in Клариназе-12 tablets?

The dye and coloring agents, along with ingredients like titanium dioxide, are listed as inactive ingredients. According to regulatory documentation, they are used for identification and structural integrity of the tablet and its coating.

Q: What should be done if someone accidentally takes more Клариназе-12 than expected?

The label advises that in the event of a suspected overdosage, medical help or contact with a Poison Control Center is recommended. This warning is due to the potential for serious adverse effects from the active ingredients.

Q: Do official sources list any specific foods or drinks to avoid while using Клариназе-12?

Regulatory information indicates that alcohol is not recommended for use with this product due to the potential for additive side effects. No specific foods are listed in the official label as being explicitly required to avoid.

Q: Do official documents mention any potential effects on laboratory test results?

Yes, official documents contain a warning regarding certain laboratory procedures. The label states that the antihistamine component (loratadine) should be discontinued approximately 48 hours prior to skin testing, due to the potential for the antihistamine component to interfere with the results.

How to Store and Dispose of Clarinase-12

The storage and disposal of Loratadine and Pseudoephedrine Sulfate extended-release tablets must strictly follow regulatory guidance to ensure product stability and safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Environment	Keep in a dry place to protect from moisture.
Packaging	Do not use if the individual safety-sealed blister unit is open or torn.
Child Safety	Keep out of reach of children.

Disposal Instructions

Disposal of unused or expired tablets must be completed according to local regulations. The official preference is to utilize a drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance and sealed in a container before being discarded with household trash. This product must not be disposed of by flushing it down a toilet or pouring it down a sink.